Omthera Pharmaceuticals Inc.

Chrysalis Pharma Ag

Sonogene LLC

Other

Novo Nordisk A/s

Davidson Lopez LLC

Michael H Davidson

Timothy J Maines

Bharat M Mehta

Gerald L Wisler

Peter Ralph Wood

Bernardus Nicolaas Machielse

Eric Coles

Bernardus N M Machielse

Madhav N Devalaraja

Roelof Rongen

Rahul Kakkar

Sadik Elshani

John F Arnett

The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.

Methods for treating IL-6 mediated inflammation without immunosuppression

DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.

DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form

The invention relates to a drug conjugate including a drug and a plant steroid. The drug conjugate may target the drug for intestinal cell delivery, and thus may be used to treat diseases, including intestinal diseases, or to affect intestinal metabolism. The invention therefore also relates to treating intestinal diseases and affecting intestinal metabolism with the drug conjugate.

Plant steroids and uses thereof

The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.

Compositions of statins and omega-3 fatty acids

The present invention provides methods for transfecting cells (e.g., liver cells) to express ABCA1 and increase HDL in the blood. The compositions described herein comprise a pharmaceutically acceptable aqueous carrier containing sonochemically-active microspheres together with a plasmid DNA construct encoding an active form of ABCA1 and at least one promoter for the expression thereof. Preferably, the sonochemically-active microspheres comprise, consist essentially of, or consist of gas bubbles (e.g., a fluorocarbon gas, such as octafluoropropane) encapsulated within protein-containing or lipid-containing shells (e.g., human serum albumin shells). The microspheres are disruptable by exposure to ultrasonic acoustic energy to release the encapsulated gas.

Sonochemical induction of ABCA1 expression and compositions therefor

The present invention provides compositions useful for transfecting cells (e.g., liver cells) to express ABCA1. The compositions described herein comprise a pharmaceutically acceptable aqueous carrier containing sonochemically-active microspheres together with a plasmid DNA construct encoding an active form of ABCA1 and at least one promoter for the expression thereof. Preferably, the sonochemically-active microspheres comprise, consist essentially of, or consist of gas bubbles (e.g., a fluorocarbon gas, such as octafluoropropane) encapsulated within protein-containing or lipid-containing shells (e.g., human serum albumin shells). The microspheres are disruptable by exposure to ultrasonic acoustic energy to release the encapsulated gas.

A method for transfection of DNA or RNA encoding apo A1 into the liver to regulate lipid metabolism comprises injection of a solution containing the DNA or RNA gene into the liver in combination with gas microbubbles or microspheres and using ultrasound to induce the transfection of the DNA or RNA in the liver.

Enhancement of transfection of DNA into the liver

A method for reducing the risk of atherosclerosis in a patient at risk of same comprising the steps of removing cholesterol ester transfer protein from blood of the patient to reduce the plasma CETP levels in the patient. In an embodiment, the method includes the step of passing the patient's plasma through an apheresis machine to remove at least some of the plasma cholesterol ester transfer protein.

Growing community of inventors

Highland Park, IL, United States of America

Michael H Davidson